Leaflet XIGRIS 5mg powder for solution for infusion

Indicated for: severe sepsis

Route of administration: infusion

Substance: drotrecogine alfa (coagulation factor)

ATC: B01AD10 (Blood and blood forming organs | Antithrombotic agents | Enzymes)

Drotrecogin alfa was a medication previously used for the treatment of severe sepsis with multiple organ dysfunction. It is a recombinant activated protein C that works by reducing inflammation and excessive coagulation, thereby improving blood flow and organ function.

The medication was administered intravenously, usually in a hospital setting, under medical supervision. It was used to reduce mortality associated with severe sepsis.

Side effects included bleeding, allergic reactions, and, in rare cases, severe hemorrhages. Its use has been discontinued in many countries due to limited efficacy and associated risks.

Consult your doctor to discuss available alternatives for the treatment of severe sepsis. Follow all medical recommendations to ensure the best possible care.

General data about XIGRIS 5mg

  • Substance: drotrecogine alfa
  • Date of latest medicines list: 01-07-2013
  • Product code: W12624001
  • Concentration: 5mg
  • Pharmaceutical form: powder for solution for infusion
  • Quantity: 1
  • Product type: Original
  • Prescription status: S - Medicines dispensed with a restricted medical prescription, reserved for use in certain specialized fields.

Concentrations available for drotrecogine alfa

  • 20mg
  • 5mg